Christopher Teske
Wayne State University
Highly motivated student of science intent on using my background to address and ultimately contribute to the groundbreaking research currently underway in biomedicine and translational research; pharmacotherapy and rational drug design. Particular interests include neuro/psycho/pharmacology, cellular biology, and the characterization of novel compounds to effectively treat difficult illnesses with innovative approaches; my principles lie in discerning the biological mechanisms mediating the potential therapeutic utility of psychedelics, dissociative anesthetics, and entactogens. Additional areas of professional interest and investigation include the morphogenetic etiology of left-sided obstructive heart lesions, pediatric heart failure, LVADs, the implementation of stem cell technology for therapeutic use, 3D printing and tissue engineering, and longitudinal/outcomes research concerning post-operative Congenital Heart Disease (CHD).
Preprint
Open Review
30 Aug 2022
| By
Christopher Christopher Teske

Zebrafish cardiac tissue may regenerate post-ventricular amputation via the Notch pathway. Notch is important in cellular differentiation and proliferation of cardiomyocytes. Damage results in altered hemodynamics, and the mechanosensitive ion channel Trpv4 may interact with cardiac cilia to induce the Notch pathway via Klf2. Notch stimulates downstream Erbb2 and BMP...

Preprint
Open Review
30 Aug 2022
| By
Christopher Christopher Teske

Even at therapeutic doses, ibogaine may cause potentially life-threatening cardiac arrhythmia. Science is beginning to unravel the pharmacological factors that may underlie ibogaine-induced cardiotoxicity.-Ibogaine has shown promising anti-addictive effects in both animal models and human trials, aiding those in search of a novel treatment for addiction and the compulsive behaviors...

Preprint
Open Review
30 Aug 2022
| By
Christopher Christopher Teske

As science unravels ketamine’s mechanisms of action to better understand its efficacy as an antidepressant, its antibacterial activity has been probed at the same time. Current research has found a naturally-occurring, fungal origin for the drug, exhibiting antiparasitic properties. The current onslaught of research into ketamine’s therapeutic potential has led...

Preprint
Open Review
9 Sep 2022
| By
Christopher Christopher Teske

Current research suggests that MDMA, or 3,4-methylenedioxymethamphetamine, may be particularly useful in the treatment of post-traumatic stress disorder (PTSD). Belonging to a class of substances known as entactogens, MDMA and its derivatives bear structural motifs common to both psychedelics and amphetamines, giving them a unique pharmacology with distinct subjective effects....

Preprint
Open Review
30 Aug 2022
| By
Christopher Christopher Teske

As ketamine’s demonstrable therapeutic applications have become ever more popular, earlier research lauding its potential as an antimicrobial and antiparasitic agent has quietly reemerged. The last several years have seen a palpable enthusiasm regarding ketamine’s potential utility in the treatment of depression, anxiety, and related maladies. This research culminates at...

Preprint
Open Review
30 Aug 2022
| By
Christopher Christopher Teske

Despite differing pharmacodynamics, ketamine and serotonergic psychedelics may share downstream effects crucial to their rapid and sustained antidepressant activity. Both ketamine and serotonergic psychedelics (SPs) have been studied as novel treatments for depression, particularly Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). Promising results and demonstrated benefits in preliminary research...